Mitotech S.A, a Luxembourg-based clinical-stage biotechnology company developing novel antioxidant molecules targeting mitochondria, today announced that it has achieved significant positive results ...
LUXEMBOURG, Oct. 23, 2018 /PRNewswire-PRWeb/ -- Mitotech S.A., a Luxembourg-based clinical-stage biotechnology company developing novel small molecules targeting mitochondria, today announced ...
Approximately 20 million Americans suffer from Dry Eye Disease – the itchy, uncomfortable and inconvenient condition that remains the number one reason for ophthalmologist visits. People with Dry Eye ...
HONG KONG, Oct 13, 2022 - (ACN Newswire) - Essex Bio-Technology Limited (the "Company", together with its subsidiaries, the "Group") wishes to announce that Essex Bio-Investment Limited ("Essex ...
DENVER – Treatment with the mitochondrial reactive oxygen species scavenger Visomitin resulted in reduced corneal staining and improved visual function in patients with dry eye, according to a study ...
LUXEMBOURG, Aug. 25, 2020 /PRNewswire-PRWeb/ -- Mitotech S.A, a Luxembourg-based clinical-stage biotechnology company developing novel pharmaceuticals targeting mitochondria, in partnership with Essex ...
Mitotech S.A has announced that it has achieved significant positive results in its U.S. Phase II clinical trial of SkQ1 compound in patients with moderate to severe dry eye syndrome. SkQ1 is a small ...
Russian and Swedish scientists have used an artifical antioxidant to slow the aging process is lab mice. The compound, known as SkQ1, targets mitochondria. ROBERT F. BUKATY AP File While everyone was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback